Compare MIST & ANIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MIST | ANIX |
|---|---|---|
| Founded | 2003 | 1982 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 95.3M | 114.0M |
| IPO Year | 2019 | 2013 |
| Metric | MIST | ANIX |
|---|---|---|
| Price | $0.70 | $2.63 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 4 |
| Target Price | $5.86 | ★ $9.75 |
| AVG Volume (30 Days) | ★ 1.1M | 267.0K |
| Earning Date | 11-11-2026 | 09-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 12.82 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $210,000.00 |
| Revenue This Year | $147.62 | N/A |
| Revenue Next Year | $476.43 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.70 | $2.32 |
| 52 Week High | $3.06 | $5.46 |
| Indicator | MIST | ANIX |
|---|---|---|
| Relative Strength Index (RSI) | 34.67 | 39.72 |
| Support Level | N/A | $2.62 |
| Resistance Level | $1.42 | $3.09 |
| Average True Range (ATR) | 0.06 | 0.14 |
| MACD | 0.00 | -0.01 |
| Stochastic Oscillator | 8.54 | 6.69 |
Milestone Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of cardiovascular medicines. Its approved product CARDAMYST (etripamil) nasal spray is available in the United States and is the self-administered treatment for use by patients anywhere, anytime an attack of PSVT occurs. It operates in single segment.
Anixa Biosciences Inc is a biotechnology company developing therapies and vaccines focused on critical unmet needs in oncology. Its operations are organized into reportable segments comprising Cancer Vaccines, CAR-T Therapies, and Other. The Cancer Vaccines segment involves vaccines to treat and prevent breast and ovarian cancer, as well as additional cancer vaccines targeting intractable cancers, including high-incidence malignancies in lung, colon, and prostate. The CAR-T Therapies segment involves the development of liraltagene autoleucel (lira-cel), an ovarian cancer immunotherapy using chimeric endocrine receptor-T cell technology, developed at its subsidiary, Certainty Therapeutics, Inc. The Other segment consists of legacy operations, including limited patent licensing activities.